The American Society of Hematology Annual Meeting, 2015

New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting

January 21, 2016

Evidence-Based Oncology

A session on the first day of the annual meeting of the American Society of Hematology, held December 5-8, 2015, in Orlando, Florida, clinicians discussed the promise and challenges of using newly approved hematology/oncology agents.

Abundant Optimism at the ASH/FDA Joint Symposium on New Drug Approvals in Multiple Myeloma

January 21, 2016

Evidence-Based Oncology

At a joint session at the annual meeting of the American Society of Hematology, primary clinical reviewers from the FDA discussed the safety and efficacy issues of 3 very recently approved drugs for multiple myeloma, along with 2 clinicians who have extensive experience with these drugs in the real-world setting.

Experts Share Concepts of Quality Measures and Pay-for-Performance With Hematologists

January 25, 2016

Evidence-Based Oncology

At the annual meeting of the American Society of Hematology, experts discussed quality measurement, public performance reporting, and pay-for-performance and it's impact on healthcare in the United States.

How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH

January 25, 2016

Evidence-Based Oncology

An educational session on Patient-Reported Outcomes in Hematology at the annual meeting of the American Society of Hematology, discussed the importance of embracing the patient perspective in healthcare delivery.

Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease

January 27, 2016

Evidence-Based Oncology

Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.

Insurance Status Determines OS in Patients With CML

January 27, 2016

Evidence-Based Oncology

Results presented at the annual meeting of the American Society of Hematology found that many patients diagnosed with chronic myeloid leukemia may not have access to or receive appropriate care, in part due to their insurance coverage.

Study Shows Academic Hospitals Better at Caring for ALL Patients

January 27, 2016

Evidence-Based Oncology

A study presented during a health outcomes session at the American Society of Hematology meeting evaluated the difference in overall survival in patients with acute lymphoblastic leukemia treated in academic versus nonacademic hospitals.

Healthcare Utilization in Children With Sickle Cell Disease

January 29, 2016

Evidence-Based Oncology

At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.

Does Geographic Location Influence Healthcare Utilization in Children With Lymphoma?

January 29, 2016

Evidence-Based Oncology

A study presented at the 57th meeting of the American Society of Hematology finds that distance from the site of care could could adversely affect outcomes in children with acute lymphoblastic leukemia and acute myeloid leukemia.